Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
Rani Therapeutics (Nasdaq:RANI) announced that its management will participate in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rani Therapeutics (Nasdaq:RANI) announced that its management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, at 10:00 a.m. ET.
The CEO and CFO will join a fireside chat and 1x1 meetings, with a live and replay webcast available via the company’s investor relations website.
Details
News Market Reaction – RANI
On May 13, the first trading day after this news, RANI closed 4.55% below the previous close.
Data tracked by StockTitan Argus for the May 13 session.
Key Figures
- Conference edition
- 4th Annual
- H.C. Wainwright BioConnect Investor Conference
- Conference date
- May 19, 2026
- Scheduled presentation date at BioConnect conference
- Presentation time
- 10:00 am ET
- Scheduled time for Rani’s session
- Meeting format
- Fireside chat and 1x1 meetings
- Investor conference session structure
Historical Context
-
Appointment of Dr. Sara Kenkare-Mitra as strategic advisor.
-
Q4/FY 2025 results plus Chugai deal and financing update.
-
Appointment of Jesper Høiland as Head of Strategy.
-
Announcement of date and webcast for Q4/FY 2025 results.
-
Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s management team will participate in the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. Details below:
H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Date: Tuesday, May 19, 2026 at 10:00 am E.T.
Location: NASDAQ, 151 West 42nd Street, (4 Times Square), New York, NY 10036
Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai Sanford
Format: Fireside Chat and 1x1 Meetings
Interested parties can access the live webcast for this conference from the Investor Relations section of the company's website at www.ranitherapeutics.com. The webcast replay will be available after the conclusion of the presentation.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.